NSP3 Activators

NSP3 Activators are a group of chemicals that can enhance the functional activity of NSP3 by primarily inhibiting the activity of various kinases that are known to downregulate NSP3. These kinases include protein kinase C (PKC), phosphoinositide 3-kinases (PI3K), MEK1/2, Src family kinases, JNK, Rho-associated protein kinases (ROCK), EGFR tyrosine kinase, and mTOR. By inhibiting these kinases, the NSP3 Activators can prevent kinase-dependent phosphorylation and subsequent downregulation of NSP3, leading to an enhanced functional activity of NSP3.

The NSP3 Activators include Bisindolylmaleimide I, LY294002, PD98059, Staurosporine, U0126, Wortmannin, PP2, SP600125, Y-27632, AG1478, SU6656, andRapamycin. These chemicals disrupt the kinase-dependent signaling pathways, thereby preventing the downregulation of NSP3. For instance, Bisindolylmaleimide I and Staurosporine inhibit PKC to prevent PKC-dependent phosphorylation of NSP3. LY294002 and Wortmannin, on the other hand, inhibit PI3K to disrupt PI3K-dependent signaling events that lead to NSP3 downregulation. PD98059 and U0126 inhibit MEK1/2 to attenuate the ERK signaling pathway, which is associated with the downregulation of NSP3. Similarly, PP2 and SU6656 inhibit Src family kinases to disrupt Src-dependent signaling pathways, while SP600125 inhibits JNK to disrupt JNK-dependent signaling pathways. Y-27632 inhibits ROCK to disrupt ROCK-dependent pathways, AG1478 inhibits EGFR to disrupt EGFR-dependent pathways, and Rapamycin inhibits mTOR to disrupt mTOR-dependent pathways. By disrupting these pathways, the NSP3 Activators enhance the functional activity of NSP3.